Yida Tang

Stories

Innovent's tafolecimab meets primary endpoint as first-line monotherapy

Leading the CREDIT-5 study

Innovent Biologics' tafolecimab cut LDL cholesterol by roughly 65% in a Phase 3 trial of patients who took no other lipid-lowering drug. The CREDIT-5 result is the first late-stage evidence that a Chinese-made PCSK9 antibody works as a stand-alone first-line treatment for high cholesterol.

Updated Yesterday